Young Patients Undergoing Resection of Pancreatic Cancer Fare Better than their Older Counterparts
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The median age of pancreatic ductal adenocarcinoma (PDAC) patients is 71 years. PDAC rarely affects individuals under the age of 45. We investigated features of PDAC occurring in young patients (≤45 years) who underwent surgical resection in order to determine if any difference exists in comparison to elderly patients (≥70 years).
A retrospective analysis of patients with PDAC who were ≤ 45 years on the date of surgery between 1975 and 2009 was performed. This cohort was compared with PDAC patients whose ages were over 70 years on the date of surgery over the same time interval. Information reviewed included demographics, Charlson Age–Comorbidity Index (CACI), pathological staging, surgical management, and death or last follow-up.
Seventy five patients with PDAC of age ≤ 45 years at surgery were identified. The reference group consisted of 870 patients with a median age of 75. The most common symptoms of young patients were jaundice (45 %), abdominal pain (32 %), or weight loss (33 %). This did not differ significantly from older patients. Among the younger patients, 7 (9 %) underwent total pancreatectomy, 60 (80 %) underwent pancreaticoduodenectomy, and 8 (11 %) had distal pancreatectomy. The distribution of type of surgery was similar between two groups. Fifty-two of the young patients (69 %) had an R0 resection and this did not differ from the older age group (n = 616; 71 %). The rate of lymph node positivity was 68 % for younger patients and 74 % for older patients (p = 0.27). Of the younger patients, 11, 13, 49, and 2 were classified as stage I, IIA, IIB, and III, respectively, and did not differ from the older age group. The median overall survival for the young patients cohort was 19 months (95 % CI 15–22 months) which is longer than 16 months (95 % CI 14–17 months) of the older group (p = 0.007). The actual 5- and 10- year survival in young age group (24 and 17 %) was longer than that in old age group (11 and 3 %) (p < 0.05). The median CACI of the younger patients was 0.5 and was lower than 4.1 of the older patients (p < 0.0001).
The demographic, pathologic, and treatment characteristics of PDAC patients younger than 45 years were similar to those older than 70 years. Younger patients had fewer complications after curative resections. The better survival among younger patients is likely related to fewer comorbidities in this group. These findings will be useful in counseling young patients with resectable pancreatic cancer.
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. Sep-Oct 2010;60(5):277-300.
- Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg. Nov 2006;10(9):1199-1210; discussion 1210-1191.
- Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. Jul 2006;244(1):10-15.
- de Jong MC, Li F, Cameron JL, et al. Re-evaluating the impact of tumor size on survival following pancreaticoduodenectomy for pancreatic adenocarcinoma. J Surg Oncol. Jun 1 2011;103(7):656-662.
- Bergmann F, Aulmann S, Wente MN, et al. Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. J Clin Pathol. Jun 2006;59(6):580-584.
- Duffy A, Capanu M, Allen P, et al. Pancreatic adenocarcinoma in a young patient population—12-year experience at Memorial Sloan Kettering Cancer Center. J Surg Oncol. Jul 1 2009;100(1):8-12.
- Luttges J, Stigge C, Pacena M, Kloppel G. Rare ductal adenocarcinoma of the pancreas in patients younger than age 40 years. Cancer. Jan 1 2004;100(1):173-182.
- Soliman AS, El-Ghawalby N, Ezzat F, et al. Unusually high rate of young-onset pancreatic cancer in the East Nile Delta region of Egypt. Int J Gastrointest Cancer. 2002;32(2-3):143-151.
- Ferrone CR, Brennan MF, Gonen M, et al. Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. Apr 2008;12(4):701-706.
- Baxter NN, Whitson BA, Tuttle TM. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol. Apr 2007;14(4):1320-1326.
- Ouellette JR, Small DG, Termuhlen PM. Evaluation of Charlson-Age Comorbidity Index as predictor of morbidity and mortality in patients with colorectal carcinoma. J Gastrointest Surg. Dec 2004;8(8):1061-1067.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
- Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP. Update on familial pancreatic cancer. Adv Surg. 2010;44:293-311.
- Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality, 1973-1995: a report card for the U.S. Cancer. Mar 15 1998;82(6):1197-1207.
- Ahmad NA, Lewis JD, Ginsberg GG, et al. Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am J Gastroenterol. Sep 2001;96(9):2609-2615.
- Cleary SP, Gryfe R, Guindi M, et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg. May 2004;198(5):722-731.
- Han SS, Jang JY, Kim SW, Kim WH, Lee KU, Park YH. Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas. Apr 2006;32(3):271-275.
- Young Patients Undergoing Resection of Pancreatic Cancer Fare Better than their Older Counterparts
Journal of Gastrointestinal Surgery
Volume 17, Issue 2 , pp 339-344
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Pancreas surgery
- Industry Sectors
- Author Affiliations
- 1. Department of Surgery, Johns Hopkins University School of Medicine, 600 N Wolfe St, Osler 624, Baltimore, MD, 21287, USA
- 5. The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, 600 N Wolfe St, Osler 624, Baltimore, MD, 21287, USA
- 2. Department of Pathology, Johns Hopkins University School of Medicine, 600 N Wolfe St, Osler 624, Baltimore, MD, 21287, USA
- 3. Department of Radiation Oncology, Johns Hopkins University School of Medicine, 600 N Wolfe St, Osler 624, Baltimore, MD, 21287, USA
- 4. Department of Medical Oncology, Johns Hopkins University School of Medicine, 600 N Wolfe St, Osler 624, Baltimore, MD, 21287, USA